Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Behavioral Intervention, Interview, Survey Administration.
- Who it may be relevant to
- Registry conditions: Ovarian Carcinoma, Psychiatric Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Adaptation of Helping Ovarian Cancer Patients Cope (HOPE) for Clinician Burnout (HOPE-C)
Overview
This clinical trial tests an adapted version of the Helping Ovarian Cancer Patients Cope (HOPE) intervention to address burnout among gynecologic oncology clinicians. Stress and burnout among gynecologic oncology clinicians can have far-reaching impacts not only on physicians at the individual level (e.g., distress, mental illness) but also at the professional (e.g., worse patient outcomes, increased errors) and societal levels (fewer physicians in this specialty, more system strain). The original Helping Ovarian Cancer Patients Cope (HOPE) is a workshop to promote hope among patients with ovarian cancer through creating positive narratives using the hope theory and social-cognitive theory. The adapted intervention for clinicals (HOPE-C) will use the same concepts but tailored to clinician experiences by fostering peer support and retelling their challenging stories and may address burnout for gynecologic oncology clinicians.
Detailed description
OUTLINE:
OBJECTIVE 1 DEVELOPMENT OF INTERVENTION: Clinicians review HOPE-C intervention materials and complete an interview and questionnaire on study.
OBJECTIVE 2 PILOT TRIAL: Clinicians attend HOPE-C sessions (changing their narrative, managing life's uncertainty and finding meaning) once weekly for 4 weeks, with each session lasting approximately 30-45 minutes. Clinicians complete a questionnaire before and after completing all HOPE-C sessions.
OBJECTIVE 3: Clinicians may undergo an interview after completing HOPE-C sessions.
Interventions
- Behavioral Behavioral Intervention
Complete HOPE-C sessions - Other Interview
Complete interview - Other Survey Administration
Ancillary studies
Primary outcome measures
- Objective 1: Clinician feedback for Helping Ovarian Cancer Patients Cope-Clinician Burnout (HOPE-C) [Time frame: Day 1]
- Objective 2: Feasibility (Accrual rate) [Time frame: At time of enrollment]
- Objective 2: Feasibility (Rate of intervention completion) [Time frame: At 4 weeks]
- Objective 2: Feasibility (Rate of survey completion) [Time frame: At baseline and 2-week post-intervention]
- Objective 2: Acceptability of HOPE-C [Time frame: At 2-week post-intervention]
- Objective 2: Satisfaction of HOPE-C [Time frame: At 2-week post-intervention]
- Objective 3: Optimization of the intervention [Time frame: At 2-week post-intervention]
- Objective 3: Delivery of the intervention [Time frame: At 2-week post-intervention]
Eligibility criteria
Inclusion criteria
- Age 18 years of age or older
- English speaking
- Able to provide informed consent
- Working with patients with ovarian cancer (gynecologic oncologists, medical oncologists, nurses, social workers, and advance practice providers \[APPs\])
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Health services research
Study locations
United States · 1 center
- Fred Hutch/University of Washington Cancer Consortium — Seattle
Identifiers
NCT: NCT07282158 · RG1125922 · NCI-2025-07869 · FHIRB0021069